This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.
Already Have An Account? Log in Now
Impact of T-Cell Subset Changes on Anti–PD-1 Efficacy in Metastatic Urothelial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Anti-PD1 efficacy in metastatic urothelial cancer patients associates with intra-tumoral juxtaposition of T helper-type 1 and CD8+ T-cells
Clin. Cancer Res 2021 Oct 06;[EPub Ahead of Print], M Rijnders, HE Balcioglu, DGJ Robbrecht, AAM Oostvogels, R Wijers, MJB Aarts, P Hamberg, GJLH van Leenders, JA Nakauma-González, J Voortman, HM Westgeest, JL Boormans, R de Wit, M Lolkema, AAM van der Veldt, R DebetsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.